Drugs / PB016
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05771155 | Jul 2023 → Sep 2025 overdue | ulcerative colitis | Polpharma Biologics S.A. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PB016 | “PB016 will be administered to patients with moderately to severely active UC on Weeks 0, 2 and 6, and once every 8 weeks thereafter, per the approved dosing regimen of Entyvio®” NCT05771155 ↗ |
| Route | Intravenous | “intravenous infusions of either PB016 or Entyvio® at a dose of 300 mg at Weeks 0 and 2” NCT05771155 ↗ |